Payment overview · 2025
General Payments
$123.26
1 reported records · 1 companies
Healthcare provider profile · identity verified
Michael Claude Lysek, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MOBILE, AL · NPI 1265968853
Verified facts
What the public records show
CMS Open Payments records show Michael Claude Lysek, M.D. received $123.26 in general payments during 2025 across 1 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $123.26 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $123.26 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $123.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 366 | 85 |
| Eliquis | Apixaban | 248 | 52 |
| Gabapentin | Gabapentin | 210 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 181 | 56 |
| Furosemide | Furosemide | 171 | 59 |
| Quetiapine Fumarate | Quetiapine Fumarate | 149 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 149 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 140 | 38 |
| Mirtazapine | Mirtazapine | 136 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 134 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 129 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 111 | 44 |
| Carvedilol | Carvedilol | 109 | 27 |
| Losartan Potassium | Losartan Potassium | 109 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 30 |
| Lisinopril | Lisinopril | 101 | 20 |
| Potassium Chloride | Potassium Chloride | 96 | 26 |
| Metformin Hcl | Metformin Hcl | 94 | 20 |
| Trazodone Hcl | Trazodone Hcl | 86 | 26 |
| Nifedipine Er | Nifedipine | 81 | 21 |
| Sertraline Hcl | Sertraline Hcl | 74 | 16 |
| Buspirone Hcl | Buspirone Hcl | 72 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 21 |
| Memantine Hcl | Memantine Hcl | 67 | 17 |
| Risperidone | Risperidone | 63 | 12 |
| Olanzapine | Olanzapine | 62 | 14 |
| Allopurinol | Allopurinol | 54 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 25 |
| Amiodarone Hcl | Amiodarone Hcl | 52 | 17 |
| Finasteride | Finasteride | 51 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 50 | 15 |
| Omeprazole | Omeprazole | 47 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 46 | 22 |
| Spironolactone | Spironolactone | 46 | 16 |
| Famotidine | Famotidine | 44 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 35 |
| Torsemide | Torsemide | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 38 | 13 |
| Levetiracetam | Levetiracetam | 37 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 22 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 37 | 36 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 36 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 35 | 20 |
| Baclofen | Baclofen | 34 | suppressed |
| Entresto | Sacubitril/Valsartan | 34 | 12 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 33 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 33 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 27 |
| Divalproex Sodium | Divalproex Sodium | 31 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 23 |
| Novolog Flexpen | Insulin Aspart | 30 | 15 |
| Bumetanide | Bumetanide | 29 | suppressed |
| Rexulti | Brexpiprazole | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 24 |
| Jardiance | Empagliflozin | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Cefdinir | Cefdinir | 25 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | 11 |
| Pregabalin | Pregabalin | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Nystatin | Nystatin | 24 | 17 |
| Sucralfate | Sucralfate | 24 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | 11 |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 20 |
| Clonazepam | Clonazepam | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 15 |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Lactulose | Lactulose | 18 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 17 | 12 |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 15 |
| Lovastatin | Lovastatin | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Ingrezza | Valbenazine Tosylate | 16 | suppressed |
| Austedo | Deutetrabenazine | 15 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Prednisone | Prednisone | 15 | 14 |
| Trulicity | Dulaglutide | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 11 |
| Tradjenta | Linagliptin | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Permethrin | Permethrin | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $123.26 · 1 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Teva Pharmaceuticals USA, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error